サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1588573

統合臓器支持療法の世界市場：2024年～2031年

Global Integrated Organ Support Therapies Market - 2024-2031

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
統合臓器支持療法の世界市場：2024年～2031年
出版日: 2024年11月08日
発行: DataM Intelligence
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

統合臓器支持療法の世界市場は、2023年に39億1,000万米ドルに達し、2031年には59億6,000万米ドルに達すると予測され、予測期間2024-2031年のCAGRは5.5%で成長する見込みです。

統合臓器支持療法は、重症患者の1つまたは複数の機能不全臓器の機能を維持、支持、または一時的に代替するように設計された、集学的かつ協調的な一連の医療介入および医療機器です。これらの治療法は、主に集中治療室や急性期医療の現場で、患者が多臓器不全、敗血症、呼吸困難、急性腎障害、肝不全などの重篤な健康状態に苦しんでいる場合に用いられます。

統合臓器支持療法は、臓器機能を維持することで不可逆的な損傷を防ぎ、根本的な原因が治療されるか身体が回復するまでの間、患者を安定させることを目的としています。例えば、organdonor.govによると、103,223人の男性、女性、子供が全米の移植待機リストに載っており、このような場合、これらの統合臓器支持療法が役立つ可能性があります。

市場力学：

促進要因

慢性・急性臓器不全の有病率の上昇

慢性および急性臓器不全の有病率の増加は、複数の臓器の機能を同時に管理または代替できる統合臓器支持療法に対する需要の高まりに直結しています。慢性の臓器不全も急性の臓器不全も、身体に必要な機能を果たす能力を損なうため、これらの機能不全に陥った臓器を一時的に代替・支援できる統合臓器支持装置や治療法が必要となります。

例えば、米国国立衛生研究所（NIH）が実施した研究によると、新たな臓器不全の発生率は1,342/100,000人年であり、全救急科受診者の有病率は5.2％でした。臓器不全患者の1年全死亡率は29.8％でした。臓器不全が増加傾向にあることから、総合的な臓器補助療法の需要は継続的に拡大すると予想されます。

抑制要因

臓器支持療法や機器に関連するリスクや合併症、臓器支持機器や療法の高額なコスト、複雑な規制当局の承認プロセス、高い保守・運用要件、機器の可搬性や可動性の制限といった要因が、統合臓器支持療法市場の阻害要因になると予想されます。

これらの治療法は多臓器不全患者の管理に不可欠であるが、関連するリスク、合併症、潜在的な副作用がその導入と有効性に影響を及ぼす可能性があります。また、このようなデバイスの使用は複雑であるため、ヘルスケアシステムにさらなる負担をかけることになり、市場の成長を妨げる可能性があります。

例えば、臓器支持療法に関連する最も深刻な合併症の1つは感染リスクの増大であり、特に体外膜酸素療法（ECMO）や持続的腎代替療法（CRRT）のような侵襲的な装置では顕著です。特にECMOやCRRTなど多くの臓器補助装置は体外で血液を循環させるため、血栓形成や出血のリスクが高いです。こうしたリスクが市場の成長を妨げる可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 慢性・急性臓器不全の有病率の上昇
      • 臓器支持デバイスの技術的進歩
    • 抑制要因
      • 臓器支持療法とデバイスに関連するリスクと合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 特許分析
  • 規制分析
  • SWOT分析
  • アンメットニーズ

第6章 治療タイプ別

  • 体外式膜酸素療法（ECMO）
    • 静脈（VV）
    • 静脈-動脈（VA）
    • 動脈-静脈（AV）
  • 持続的腎代替療法（CRRT）
    • 持続的静脈血液濾過療法（CVVH）
    • 持続的静脈血液透析（CVVHD）
    • 持続的静脈血液濾過透析（CVVHDF）
    • 緩徐連続限外濾過（SCUF）
  • 体外式CO2除去（ECCO2R）
  • 肝臓サポートシステム
    • 分子吸着剤循環システム
    • バイオ人工肝臓
  • 心臓補助装置
    • 大動脈内バルーンポンプ
    • 心室補助装置
    • 人工臓器全体

第7章 モダリティ別

  • ポータブル/トランスポータブルデバイス
  • ベッドサイドデバイス
  • 埋め込み型デバイス

第8章 用途別

  • 呼吸不全
  • 心不全
  • 肝不全
  • 腎不全
  • 多臓器不全

第9章 患者タイプ別

  • 成人患者
  • 小児患者
  • 新生児患者

第10章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • 集中治療室（ICU）

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Emulate, Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Baxter International Inc.
  • Fresenius Medical Care AG
  • Getinge AB
  • LivaNova, Inc.
  • Asahi Kasei Corporation
  • ADVITOS GmbH
  • NIHON KOHDEN CORPORATION
  • Vapotherm
  • Fisher & Paykel Healthcare Limited

第14章 付録

目次
Product Code: OT8718

Overview

The global integrated organ support therapies market reached US$ 3.91 billion in 2023 and is expected to reach US$ 5.96 billion by 2031, growing at a CAGR of 5.5% during the forecast period 2024-2031.

Integrated organ support therapies are a multidisciplinary and coordinated set of medical interventions and devices that are designed to sustain, support or temporarily replace the functions of one or multiple failing organs in critically ill patients. These therapies are primarily used in intensive care units and acute care settings where patients suffer from severe health conditions, including multi-organ failure, sepsis, respiratory distress, acute kidney injury or liver failure and among others.

Integrated organ support therapies aim to maintain organ functions to prevent irreversible damage and stabilize patients while underlying causes are treated or the body heals. For instance, according to organdonor.gov, 103,223 men, women and children are on the national transplant waiting list, in such cases, these integrated organ support therapies may be helpful, which further helps to boost the market growth.

Market Dynamics: Drivers

Rising prevalence of chronic and acute organ failures

The increasing prevalence of both chronic and acute organ failures directly correlates with the rising demand for integrated organ support therapies that can manage or replace the function of multiple organs simultaneously, as these conditions significantly increase the need for life-support interventions and multi-organ management. Both chronic and acute organ failures impair the body's ability to perform essential functions, necessitating integrated organ support devices and therapies that can temporarily replace or support these failing organs.

For instance, according to the study conducted by the National Institute of Health (NIH), the study revealed the incidence of new organ failure at 1,342/1,00,000 person-years and a prevalence of 5.2% of all emergency department contacts. One-year all-cause mortality was 29.8% among organ failure patients. As organ failures are on the rise, the demand for integrated organ support therapies is expected to grow continuously.

Restraints

Factors such as risks and complications associated with organ support therapies and devices, high costs of organ support devices and therapies, complex regulatory approval processes, high maintenance and operational requirements and limited portability and mobility of devices are expected to hamper the integrated organ support therapies market.

While these therapies are essential for managing patients with multi-organ failure, the associated risks, complications and potential side effects can affect their adoption and efficacy. The complexity of using such devices also places an additional burden on healthcare systems, which can hamper the growth of the market.

For instance, one of the most serious complications associated with organ support therapies is the increased risk of infection, especially with invasive devices like extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Many organ support devices, particularly ECMO and CRRT, involve circulating blood outside the body, this further poses a significant risk of blood clot formation or bleeding. These risks may hamper the growth of the market.

Segment Analysis

The global integrated organ support therapies market is segmented based on therapy type, modality, application, patient type, end-user and region.

The multi-organ failure from the application segment accounted for approximately XX% of the global integrated organ support therapies market share

The multi-organ failure segment is expected to hold the largest market share over the forecast period. Integrated organ support therapies are critical in the management of multi-organ failure, a condition where two or more organs fail simultaneously, often resulting from severe infections, trauma or underlying chronic conditions. These therapies provide life-sustaining support to failing organs, enabling doctors to stabilize the patient while the underlying causes are treated or recovery occurs.

For instance, according to a study conducted by ScienceDirect, in surgical critical care units, 50-80% of all deaths are due to multiple organ failure (MOF). The origin of MOF is still not well understood, therapy is still mainly supportive and the death rate (30-70% in most series) has not significantly decreased even though the syndrome was first identified more than 20 years ago. Thus, the rising burden of MOF further increases the demand for integrated organ support therapies.

Geographical Analysis

North America accounted for approximately XX% of the global integrated organ support therapies market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of chronic diseases and critical illnesses and high healthcare expenditure. Chronic diseases and critical illnesses are the leading causes of organ failure in the region especially in the United States, directly driving the need for integrated organ support therapies. Conditions such as cardiovascular diseases, chronic kidney disease (CKD), diabetes and respiratory diseases significantly increase the incidence of multi-organ failure, where organ support therapies become crucial for patient survival.

For instance, according to the American Kidney Fund Organization, about 808,000 Americans are living with kidney failure. According to the CDC, the US Department of Health and Human Services estimated that 129 million Americans suffer from at least one severe chronic disease.

The U.S. healthcare system is the largest spender on healthcare globally. For instance, according to the U.S. Centers for Medicare & Medicaid Services, US healthcare spending grew 4.1 percent in 2022, reaching $4.5 trillion or $13,493 per person. As a share of the nation's GDP, health spending accounted for 17.3%, which includes significant expenditures on critical care technologies, including ECMO, CRRT and others.

Market Segmentation

By Therapy Type

  • Extracorporeal Membrane Oxygenation (ECMO)
    • Veno-Venous (VV)
    • Veno-Arterial (VA)
    • Arterio-Venous (AV)
  • Continuous Renal Replacement Therapy (CRRT)
    • Continuous Venovenous Hemofiltration (CVVH)
    • Continuous Venovenous Hemodialysis (CVVHD)
    • Continuous Venovenous Hemodiafiltration (CVVHDF)
    • Slow Continuous Ultrafiltration (SCUF)
  • Extracorporeal CO2 Removal (ECCO2R)
  • Liver Support Systems
    • Molecular Adsorbent Recirculating System
    • Bioartificial Liver Support
  • Cardiac Assist Devices
    • Intra-aortic Balloon Pump
    • Ventricular Assist Devices
    • Total Artificial Organs

By Modality

  • Portable/Transportable Devices
  • Bedside Devices
  • Implantable Devices

By Application

  • Respiratory Failure
  • Cardiac Failure
  • Liver Failure
  • Kidney Failure
  • Multi-Organ Failure

By Patient Type

  • Adult Patients
  • Pediatric Patients
  • Neonatal Patients

By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Intensive Care Units (ICUs)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • The rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the integrated organ support therapies market include Emulate, Inc., Baxter International Inc., Fresenius Medical Care AG, Getinge AB, LivaNova, Inc., Asahi Kasei Corporation, ADVITOS GmbH, NIHON KOHDEN CORPORATION, Vapotherm, Fisher & Paykel Healthcare Limited and among others.

Key Developments

  • In August 2024, Talphera, Inc. declared that the NEPHRO CRRT study's first patient has been recruited. 166 individuals receiving continuous renal replacement therapy (CRRT) at up to 14 clinical locations across the US will be included in the NEPHRO CRRT registrational research. The mean post-filter activated clotting time for circuits injected with nafamostat versus placebo for the first 24 hours is the study's main outcome.
  • In April 2022, Baxter International Inc. released the U.S. Food and Drug Administration (FDA) 510(k) clearance 0f ST Set for use in continuous renal replacement therapy (CRRT). The ST Set is a disposable, extracorporeal (outside the body) circuit that comes pre-connected and may be used with the PrisMax or Prismaflex control units (monitors). It purifies blood through a semipermeable membrane.

Why Purchase the Report?

  • To visualize the global integrated organ support therapies market segmentation based on therapy type, modality, application, patient type, end-user and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of the integrated organ support therapies market with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global integrated organ support therapies market report would provide approximately 78 tables, 77 figures and 179 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Therapy Type
  • 3.2. Snippet by Modality
  • 3.3. Snippet by Application
  • 3.4. Snippet by Patient Type
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Prevalence of Chronic and Acute Organ Failure
      • 4.1.1.2. Technological Advancements in Organ Support Devices
    • 4.1.2. Restraints
      • 4.1.2.1. Risks and Complications Associated with Organ Support Therapies and Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Therapy Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 6.1.2. Market Attractiveness Index, By Therapy Type
  • 6.2. Extracorporeal Membrane Oxygenation (ECMO)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Veno-Venous (VV)
    • 6.2.4. Veno-Arterial (VA)
    • 6.2.5. Arterio-Venous (AV)
  • 6.3. Continuous Renal Replacement Therapy (CRRT)
    • 6.3.1. Continuous Venovenous Hemofiltration (CVVH)
    • 6.3.2. Continuous Venovenous Hemodialysis (CVVHD)
    • 6.3.3. Continuous Venovenous Hemodiafiltration (CVVHDF)
    • 6.3.4. Slow Continuous Ultrafiltration (SCUF)
  • 6.4. Extracorporeal CO2 Removal (ECCO2R)
  • 6.5. Liver Support Systems
    • 6.5.1. Molecular Adsorbent Recirculating System
    • 6.5.2. Bioartificial Liver Support
  • 6.6. Cardiac Assist Devices
    • 6.6.1. Intra-aortic Balloon Pump
    • 6.6.2. Ventricular Assist Devices
    • 6.6.3. Total Artificial Organs

7. By Modality

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 7.1.2. Market Attractiveness Index, By Modality
  • 7.2. Portable/Transportable Devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bedside Devices
  • 7.4. Implantable Devices

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Respiratory Failure*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiac Failure
  • 8.4. Liver Failure
  • 8.5. Kidney Failure
  • 8.6. Multi-Organ Failure

9. By Patient Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 9.1.2. Market Attractiveness Index, By Patient Type
  • 9.2. Adult Patients*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Pediatric Patients
  • 9.4. Neonatal Patients

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Intensive Care Units (ICUs)

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Emulate, Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Baxter International Inc.
  • 13.3. Fresenius Medical Care AG
  • 13.4. Getinge AB
  • 13.5. LivaNova, Inc.
  • 13.6. Asahi Kasei Corporation
  • 13.7. ADVITOS GmbH
  • 13.8. NIHON KOHDEN CORPORATION
  • 13.9. Vapotherm
  • 13.10. Fisher & Paykel Healthcare Limited

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us